Price
No data yet.
Social Signal Score
Analyst Ratings
17 analystsRevenue
$5.44M-31.94%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Andre Choulika
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 229
- Beta
- 3.20
- Country
- FR
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -4.00
Financials
Revenue
$5.44M-31.9%Net Income
$-61.47MEBITDA
$-54.38MFree Cash Flow
$-17.58M-666.0%EPS (diluted)
$-0.61Shares Outstanding (diluted)
100.71M+181.4%Operating Expenses
$59.95MCash & Debt
$146.71MReturn of Capital
$0.00Revenue by Segment (annual)
$25.73MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $72.95M | $-67.59M | $-0.68 |
| 2024 | $41.51M | $-36.76M | $-0.41 |
| 2023 | $755.0K | $-101.06M | $-1.77 |
| 2022 | $19.17M | $-106.14M | $-2.33 |
| 2021 | $30.35M | $-114.20M | $-2.69 |
| 2020 | $51.06M | $-81.07M | $-1.71 |
| 2019 | $15.19M | $-102.09M | $-2.14 |
| 2018 | $12.73M | $-78.69M | $-1.93 |
| 2017 | $25.19M | $-99.37M | $-2.78 |
| 2016 | $42.58M | $-63.92M | $-1.81 |
| 2015 | $55.04M | $-22.46M | $-0.66 |
| 2014 | $26.30M | $24.3K | $0.00 |
| 2013 | $22.82M | $-84.28M | $-4.08 |
| 2012 | $27.81M | $-29.45M | $-1.48 |
Valuation
CLLShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
110+120.00%Social Signal Score
Mentions (15)
- Newsseekingalpha.com·9d ago·Positive
Cellectis S.A. (CLLS) Q3 2026 Earnings Call Transcript Cellectis S.A. (CLLS) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·9d ago·Neutral
What Cellectis (CLLS) Said on Its Q3 Earnings Call Cellectis NASDAQ: CLLS said its cash runway is expected to extend into the second half of 2028 once its planned restructuring is fully implemented, giving the gene editing company time to reach anticipated initial clinical readouts for its two lead programs.
View source ↗ - Newsglobenewswire.com·13d ago·Neutral
Cellectis to Report Third Quarter Financial Results on November 12, 2026 NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment, will report financial results for the third quarter 2026 ending September 30, 2026 on Thursday, November 12, 2026 after the close of the U.S. market.
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
Cellectis présente de nouvelles données précliniques démontrant une édition efficace du gène APOC3 et une réduction marquée des triglycérides avec .HEAL-101 à l’ESGCT 2026 Un taux d'édition in vivo du gène APOC3 humain atteignant 70% après une seule administration Une réduction de 76 % du taux de triglycérides après une dose unique dans un modèle murin de la maladie NEW YORK, 27 oct.
View source ↗ - Newsglobenewswire.com·26d ago·Negative
… APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026 NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment, today announced the presentation of preclinical data supporting .HEAL-101, its in vivo base editing product candidate targeting APOC3 for severe hypertriglyceridemia (sHTG), at the Annual Congress of the European …
View source ↗ - Newsglobenewswire.com·38d ago·Neutral
Cellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G. BENSALEM, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G.
View source ↗ - Newsglobenewswire.com·39d ago·Negative
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. LOS ANGELES, Oct. 14, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS) on behalf of investors concerning the Company's possible violations of federal securities laws.
View source ↗ - Newsmarketbeat.com·52d ago·Neutral
Cellectis Unveils In Vivo Gene-Editing Plans for Severe Lipid Disorders Cellectis NASDAQ: CLLS outlined plans to advance two preclinical in vivo gene-editing candidates for severe forms of dyslipidemia, targeting hypertriglyceridemia and hypercholesterolemia through one-time intravenous treatments.
View source ↗ - Newsbusinesswire.com·64d ago·Negative
CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $CLLS--CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law.
View source ↗ - Newsbusinesswire.com·67d ago·Negative
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS) on behalf of investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON CELLECTIS S.A. (CLLS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURS…
View source ↗ - Newsbenzinga.com·68d ago·Negative
This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
View source ↗ - Newsseekingalpha.com·69d ago·Positive
Cellectis S.A. (CLLS) Discusses Strategic Transformation and In Vivo Gene Editing Pipeline Update Transcript Cellectis S.A. (CLLS) Discusses Strategic Transformation and In Vivo Gene Editing Pipeline Update Transcript
View source ↗ - Newsbenzinga.com·69d ago·Neutral
Corning, Cellectis, Biodexa Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures were lower this morning, with the Nasdaq 100 futures falling around 500 points on Monday.
View source ↗ - Newsglobenewswire.com·69d ago·Positive
Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a pioneer in gene editing, announced that on September 11, 2026, the board of directors approved a strategic transformation to become an in vivo gene editing company focused on developing long-lasting treatments for chronic diseases.
View source ↗ - Newsglobenewswire.com·72d ago·Neutral
Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will host a conference call and webcast on Monday, September 14, 2026 to provide a business update.
View source ↗
Earnings
Thu, Mar 4(in 3 months)
Consensus estimate $-0.26 per share
Typical surprise +5.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 12$-0.61 vs $-0.18miss
- Thu, Aug 6$-0.22 vs $-0.26beat
- Mon, May 11$-0.18 vs $-0.26beat
- Thu, Mar 19$-0.26 vs $-0.20miss
- Fri, Nov 7$0.01 vs $-0.10beat
- Mon, Aug 4$-0.24 vs $-0.10miss
Estimates and results for CLLS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in CLLS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
